Oil company Natural Resources and medical-device maker Beta Bionics shrug off a down market to gain in their trading debuts.

Shares of newly public Metsera (MTSR), which is developing ultra-long-acting obesity drugs, rallied 54% following a $275M initial public offering. Read more here.

Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion. The strong market debut of ...

Metsera, along with Maze Therapeutics, gave U.S. health care first-time share sales its best month since October.

Metsera, a clinical-stage biotechnology firm, debuted on the Nasdaq Global Select Market today. After initially offering its ...

Shares of Infinity Natural Resources jumped almost 11% in their NYSE debut, valuing the oil and natural gas producer at $1.3B. The listing ...

Recent health news highlights include a review of the safety of Alzheimer's drug Leqembi, legal charges against a New York ...

Investors clamouring for exposure to US technology firms drove structured products volumes to record heights in 2024, underlining how the tech and AI frenzy has permeated the complex ecosystem ...